News

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

2 years ago

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial

Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data…

2 years ago

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

- Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company - - This Phase 1 Healthy…

2 years ago

BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression

VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

2 years ago

Collegium Appoints Neil McFarlane to its Board of Directors

STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today…

2 years ago

New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure

Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice…

2 years ago

Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies

Tuesday, April 12th @ 12:30 pm ETCOPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”…

2 years ago

Context Therapeutics® to Participate in Two April 2022 Investor Conferences

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company…

2 years ago

TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I &…

2 years ago